Solanezumab (LY2062430) is a humanized monoclonal antibody that binds to the 
central region of β-amyloid, a peptide believed to play a key role in the 
pathogenesis of Alzheimer's disease (AD). Eli Lilly & Co is developing an 
intravenous formulation of solanezumab for the treatment of mild-to-moderate AD. 
Acute and subchronic treatment with solanezumab of transgenic mice attenuated or 
reversed memory deficits with no effects on incidence or severity of cerebral 
amyloid angiopathy-associated microhemorrhages, a severe side effect associated 
with bapineuzumab, another monoclonal antibody. Phase II studies in AD patients 
have shown a good safety profile with encouraging indications on cerebrospinal 
and plasma biomarkers. The drug is currently being investigated in Phase III 
trials. While there is a strong hope that solanezumab may represent the first 
effective passive vaccine for AD treatment, skepticism still exists on the 
ability of the drug to slow the rate of deterioration in patients with fully 
established disease.